home / stock / ctmx / ctmx quote
Last: | $1.73 |
---|---|
Change Percent: | -0.57% |
Open: | $1.77 |
Close: | $1.73 |
High: | $1.7875 |
Low: | $1.72 |
Volume: | 198,849 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.73 | $1.77 | $1.73 | $1.7875 | $1.72 | 198,849 | 04-18-2024 |
$1.76 | $1.84 | $1.76 | $1.86 | $1.76 | 585,231 | 04-17-2024 |
$1.86 | $1.99 | $1.86 | $1.99 | $1.86 | 335,962 | 04-16-2024 |
$1.97 | $2.14 | $1.97 | $2.14 | $1.94 | 383,010 | 04-15-2024 |
$2.15 | $2.14 | $2.15 | $2.26 | $2.07 | 923,169 | 04-12-2024 |
$2.15 | $2.1 | $2.15 | $2.16 | $2.06 | 1,012,264 | 04-11-2024 |
$2.1 | $2.02 | $2.1 | $2.11 | $1.8 | 2,571,376 | 04-10-2024 |
$2.03 | $2.06 | $2.03 | $2.08 | $2 | 196,005 | 04-09-2024 |
$2.06 | $2.09 | $2.06 | $2.1 | $2.05 | 198,344 | 04-08-2024 |
$2.06 | $2.07 | $2.06 | $2.14 | $2.05 | 268,073 | 04-05-2024 |
$2.06 | $2.18 | $2.06 | $2.18 | $2.055 | 267,313 | 04-04-2024 |
$2.15 | $2.13 | $2.15 | $2.18 | $2.08 | 524,864 | 04-03-2024 |
$2.14 | $2.15 | $2.14 | $2.15 | $2.07 | 326,076 | 04-02-2024 |
$2.15 | $2.19 | $2.15 | $2.2 | $2.08 | 319,544 | 04-01-2024 |
$2.18 | $2.2 | $2.18 | $2.3 | $2.17 | 2,854,999 | 03-29-2024 |
$2.18 | $2.2 | $2.18 | $2.3 | $2.17 | 2,854,999 | 03-28-2024 |
$2.19 | $2.12 | $2.19 | $2.2 | $2.08 | 590,298 | 03-27-2024 |
$2.11 | $2.16 | $2.11 | $2.16 | $1.99 | 645,922 | 03-26-2024 |
$2.14 | $2.13 | $2.14 | $2.155 | $2.09 | 358,645 | 03-25-2024 |
$2.11 | $2.21 | $2.11 | $2.21 | $2.1 | 287,841 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study ( NCT06265688 ) of CX-2051 in pa...
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US co-commercialization and economic rights for select programs - SOUTH SAN FRANCISCO, Calif., ...
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally ...